Advancing a Single Shot Cure for HIV-1 Infection
Pioneering innovative strategies to cure life threatening infectious and metabolic disease
Transforming Lives by Developing Curative One Time Treatments
About us
Marguron, Inc. is exploiting breakthrough gene therapy based single shot curative treatments. Our initial focus is preventing and curing HIV-1 infection.
HIV/AIDS remains one of the most significant infectious disease threats to the population. Globally, 40 million people were living with HIV-1 in 2023. That year saw 1.3 million new infections and 630,000 deaths from AIDS-related diseases. In developed (G9) regions, 3.1 million people live with HIV. While advances in antiretroviral therapy (ART) have markedly improved the outlook for people living with HIV, the stark global statistics reflect the challenges with implementing ART, as well as the realization that this modality is not curative. The advent of long-acting ART formulations is unlikely to provide a permanent solution, as these cost- and resource burdensome therapies require life long administrations.
For this reason, Marguron is disrupting the status quo by developing curative modalities. Our approach is to make reality:
"One Shot and You are Good for Life"
Pipeline
Marguron-3A: In Preclinical Development for the Prevention, Treatment and Cure of HIV-1 infections
Harnessing innovations in antibody discovery and the industrialization of gene based medicines, our proprietary treatment used to mitigate the formation of antidrug antibodies (rapamycin, or MRG-01) administered concurrently with AAV9-delivered broadly neturalizing antibodies.
This technology is based on the original and pioneering work performed by Dr. Ronald Desrosiers and his team at the University of Miami whose pre-clinical studies in non-human primates resulted in a key publication on what is now known as "The Miami Monkey". This animal has been free of HIV for over eight years (as of September 2024). Our most recent advance overcomes a key obstacle that could allow millions of people to be cured of their HIV infection.
Rationale
Antiretroviral management of HIV-1 infection significantly reduces but does not normalize morbidity and mortality. Further, infected individuals want to be cured and free of the stigma that accompanies HIV status - an outcome not currently possible with today's approved therapeutic approaches. Because of the realization that ART alone has not ended the HIV epidemic, there remains a global effort to pursue a practical and scalable solution for HIV infection - one that removes stigmas and one that removes the enduring burdens of this disease.
Target Population
People living with HIV-1 and at risk of HIV infection: 40 million people living with HIV globally; 1.3 million incidence. 3.1 million people living with HIV in developed (G9) nations.
Extending beyond curative measures, Marguron's technology offers an approach to achieve pre-exposure prophylaxis (PreP) by creating an anbitody shield against infection.
Marguron plans to develop its technology for use in not just developed nations, but also in low and middle income countries (LMICs).
Contact Us
Please use the contact form at the right or email info(at)marguron.com